Physician profile
Fred Pescatore
NPI 1295748358
$3,359.08
in general payments reported to CMS, 2019-2025
16 companies · $178 in 2025
The $178 reported for 2025 was more than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,164 · 2020: $403 · 2021: $284 · 2022: $217 · 2023: $654 · 2024: $459 · 2025: $178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,290.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $781.73 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Greer Laboratories, INC. | $626.51 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $539.60 | 2019-2024 | Xifaxan, Trulance |
| Pfizer INC. | $243.81 | 2019-2024 | |
| Astellas Pharma US INC | $217.11 | 2019-2021 | |
| Novo Nordisk INC | $186.19 | 2023-2025 | Ozempic, Rybelsus |
| Janssen Biotech, INC. | $147.44 | 2019 | |
| Acella Pharmaceuticals, LLC | $141.69 | 2023-2025 | NP Thyroid 60 |
| Abbvie INC. | $104.80 | 2020-2021 | |
| Lilly USA, LLC | $101.54 | 2022-2024 | Mounjaro, Zepbound |
| Romark Laboratories, Lc | $84.52 | 2019-2020 | |
| Menarini Silicon Biosystems, INC. | $49.47 | 2023 | Cellsearch |
| Avion Pharmaceuticals | $44.37 | 2023-2024 | NP Thyroid 60 |
| Phadia US INC. | $34.11 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.33 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $25.86 | 2023 | Adthyza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fred Pescatore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.